Clinical Trial to Investigate Safety and Efficacy of Edoxaban in Patients With CTEPH (KABUKI)
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This is phase III trial to evaluate whether edoxaban, a direct factor Xa inhibitor, is
noninferior to warfarin in preventing worsening of chronic thromboembolic pulmonary
hypertension (CTEPH).